Compound: nateglinide
SMILES: O=C(N[C@@H](C(=O)O)Cc1ccccc1)[C@H]2CC[C@H](C(C)C)CC2
InChIKey: OELFLUMRDSZNSF-BRWVUGGUSA-N
Synonyms: nateglinide, 105816-04-4, Starlix, Starsis, senaglinide, Fastic, SDZ-DJN-608, Trazec, AY-4166, D-Nateglinide, A-4166, DJN-608, nateglinida, DJN 608, SDZ DJN 608, nateglinidum, AY 4166, CHEMBL783, AY4166, A 4166, 41X3PWK4O2, DTXSID9040687, NSC-758695, (-)-N-(trans-4-Isopropylcyclohexanecarbonyl)-D-phenylalanine, CHEBI:31897, Nateglinide [USAN:USP:INN:BAN], (2R)-3-phenyl-2-{[(1r,4r)-4-(propan-2-yl)cyclohexyl]formamido}propanoic acid, D-phenylalanine, N-((trans-4-(1-methylethyl)cyclohexyl)carbonyl)-, D-Phenylalanine, N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-, trans-N-((4-(1-Methylethyl)cyclohexyl)carbonyl)-D-phenylalanine, A4166, NATEGLINIDE (USP-RS), NATEGLINIDE [USP-RS], NATEGLINIDE (EP MONOGRAPH), NATEGLINIDE [EP MONOGRAPH], nate-glinide, NATEGLINIDE (USP MONOGRAPH), NATEGLINIDE [USP MONOGRAPH], Nateglinide (USAN:USP:INN:BAN), trans-N-{[4-(1-methylethyl)cyclohexyl]carbonyl}-D-phenylalanine, (2R)-3-phenyl-2-(((1r,4r)-4-(propan-2-yl)cyclohexyl)formamido)propanoic acid, RefChem:56719, Nateglinide (JP17/USP/INN), A10BX03, OELFLUMRDSZNSF-OFLPRAFFSA-N, NCI-C61858, N-(trans-4-(1-Methylethyl)cyclohexanecarbonyl)-D-phenylalanine, 642-283-9, N-(2-(4-(cyclohexylcarbamoylsulfamoyl)phenyl)ethyl)-5-methylpyrazine-2-carboxamide, OELFLUMRDSZNSF-BRWVUGGUSA-N, 105816-06-6, Nateglinide [INN], Nateglinide EP impurity C, SDZ-DJN 608, (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid, N-[[cis-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanine(Nateglinide Impurity), MFCD00875706, XTM4DQP5S5, n-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-d-phenylalanine, (r)-2-((1r,4r)-4-isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid, 105746-37-0, N-[(trans-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine, DTXCID7020687, N-((cis-4-Isopropylcyclohexyl)carbonyl)-D-phenylalanine, D-Phenylalanine, N-((cis-4-(1-methylethyl)cyclohexyl)carbonyl)-, N-((cis-4-(1-Methylethyl)cyclohexyl)carbonyl)-D-phenylalanine, N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine, (R)-2-(cis-4-Isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid, D-Phenylalanine, N-((4-(1-methylethyl)cyclohexyl)carbonyl)-, cis-, (2R)-2-[(4-isopropylcyclohexanecarbonyl)amino]-3-phenyl-propanoic acid, (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid, (R)-2-rel-((1r,4R)-4-Isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid, SMR000466372, CAS-105816-04-4, UNII-41X3PWK4O2, D-Phenylalanine, N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-, cis-, Nateglinide CRS, Starlix;, Fastic;, NCGC00095121-01, Starsis (TN), Nateglinide, Starlix, YM-026, Nateglinide (Starlix), Nateglinide impurity C, Nateglinide (Standard), Nateglinide cis Impurity, NATEGLINIDE [MI], UNII-XTM4DQP5S5, NATEGLINIDE [JAN], (1s,4S)-D-Nateglinide, NATEGLINIDE [USAN], NATEGLINIDE [VANDF], Nateglinide impurity C CRS, A1L9H, NATEGLINIDE [MART.], SCHEMBL22088, NATEGLINIDE [WHO-DD], Nateglinide impurity C [EP], MLS000759500, MLS001424043, MLS003915639, MLS006011429, BIDD:GT0257, Nateglinide cis-isomer [USP], SCHEMBL303827, NATEGLINIDE [EMA EPAR], GTPL6833, orb1307803, SCHEMBL9232138, Nateglinide (JP18/USP/INN), CHEMBL2114389, N-(Trans-4-Isopropylcyclohexylcarbonyl)-D-Phenyl Alanine, CHEBI:94617, HY-B0422R, MSK7194, NATEGLINIDE [ORANGE BOOK], GLXC-07314, HMS2051G20, HMS2089A10, HMS2235O08, HMS3675G17, HMS3715F12, HY-B0422, Tox21_111432, BBL033469, BDBM50344967, EBC-11228, EBC-12167, s2489, STK647123, AKOS005577723, AKOS015841612, AKOS015960899, Nateglinide, >=98% (HPLC), solid, Tox21_111432_1, AC-1690, CCG-100898, DB00731, FN26165, KS-5143, NC00148, NSC 758695, NCGC00095121-12, NCGC00095121-16, NCGC00178741-03, NCGC00271534-02, NCGC00271534-03, N0912, NATEGLINIDE CIS-ISOMER [USP IMPURITY], NATEGLINIDE IMPURITY C [EP IMPURITY], NS00000602, NS00073312, SW197528-2, D01111, EN300-303645, AB00639979-06, AB00639979-08, AB00639979-09, AB00639979-11, AB00639979_12, EN300-27126236, A1-02996, Q2254797, BRD-K44353683-001-07-5, BRD-K44353683-001-08-3, Q27166439, n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine, Z1514053266, Nateglinide, European Pharmacopoeia (EP) Reference Standard, ((1r,4R)-4-isopropylcyclohexane-1-carbonyl)-D-phenylalanine, 2-[(4-Isopropyl-cyclohexanecarbonyl)-amino]-3-phenyl-propionic acid, N-[(1r,4R)-4-(Propan-2-yl)cyclohexane-1-carbonyl]-D-phenylalanine, Nateglinide, United States Pharmacopeia (USP) Reference Standard, (2R)-3-phenyl-2-{[4-(propan-2-yl)cyclohexyl]formamido}propanoic acid, (R)-2-((1s,4S)-4-isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid, {N}-[({TRANS}-4-ISOPROPYLCYCLOHEXYL)CARBONYL]-D-PHENYLALANINE, D-Phenylalanine, N-((4-(1-methylethyl)cyclohexyl)carbonyl)-, trans-, (R)-2-rel-((1r,4R)-4-Isopropylcyclohexanecarboxamido)-3-phenylpropanoicacid
Theoretical properties:
molecular_formula: C19H27NO3
molecular_weight: 317.4 g/mol
exact_mass: 317.19909372 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 6
heavy_atom_count: 23
topological_polar_surface_area: 66.4 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: Practically insoluble
Descriptions:
pubchem: Nateglinide is an N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus. It has a role as a hypoglycemic agent and an EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor.
chebi: An <em>N</em>-acyl-<small>D</small>-phenylalanine resulting from the formal condensation of the amino group of <small>D</small>-phenylalanine with the carboxy group of <i>trans</i>-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.
chembl: NATEGLINIDE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis.
Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.